{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:18:11Z","timestamp":1761895091159},"reference-count":28,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,5,29]],"date-time":"2010-05-29T00:00:00Z","timestamp":1275091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:p>Bendamustine is a unique cytotoxic agent that has demonstrated efficacy in the treatment of indolent B\u2010cell non\u2010Hodgkin lymphomas (B\u2010NHLs). In this multicenter phase II trial, the efficacy and safety of bendamustine were evaluated in Japanese patients with relapsed or refractory indolent B\u2010NHL or mantle\u2010cell lymphoma (MCL). Patients received bendamustine (120\u2003mg\/m<jats:sup>2<\/jats:sup>) on days 1\u20132 of a 21\u2010day cycle, for up to six cycles. The primary endpoint was the overall response rate (ORR) as assessed by an extramural committee according to International Workshop Response Criteria (IWRC). Secondary endpoints included complete response (CR) rate, ORR according to Revised Response Criteria (revised RC), progression\u2010free survival (PFS), and safety. Fifty\u2010eight patients with indolent B\u2010NHL and 11 with MCL were enrolled. By IWRC, bendamustine produced an ORR of 91% (95% confidence interval [CI], 82\u201397%; 90% and 100% in patients with indolent B\u2010NHL and MCL, respectively), with a CR rate of 67% (95% CI, 54\u201378%). ORR and CR rates according to revised RC were 93% (95% CI, 84\u201398%) and 57% (95% CI, 44\u201368%), respectively. After a median follow\u2010up of 12.6\u2003months, median PFS had not been reached. Estimated PFS rates at 1\u2003year were 70% and 90% among indolent B\u2010NHL and MCL patients, respectively. Bendamustine was generally well tolerated. Reversible myelosuppression, including grade 3\/4 leukopenia (65%) and neutropenia (72%), was the most clinically significant toxicity observed. Common non\u2010hematologic toxicities included mild gastrointestinal events and fatigue. These results demonstrate the high efficacy and tolerability of single\u2010agent bendamustine in relapsed patients with indolent B\u2010NHL or MCL histologies. (ClinicalTrials.gov ID: NCT00612183). (<jats:italic>Cancer Sci<\/jats:italic> 2010;)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2010.01635.x","type":"journal-article","created":{"date-parts":[[2010,5,29]],"date-time":"2010-05-29T06:32:35Z","timestamp":1275114755000},"page":"2059-2064","source":"Crossref","is-referenced-by-count":55,"title":["Multicenter phase II study of bendamustine for relapsed or refractory indolent B\u2010cell non\u2010Hodgkin lymphoma and mantle cell lymphoma"],"prefix":"10.1111","volume":"101","author":[{"given":"Ken","family":"Ohmachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuko","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naokuni","family":"Uike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Terui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Uoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Japanese Bendamustine Lymphoma Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,8,20]]},"reference":[{"key":"e_1_2_8_2_2","first-page":"74","article-title":"Global cancer statistics, 2002, updated as of October 27, 2009","volume":"55","author":"Parkin DM","year":"2009","journal-title":"CA Cancer J Clin"},{"volume-title":"Cancer Facts & Figures 2009","year":"2009","author":"American Cancer Society","key":"e_1_2_8_3_2"},{"volume-title":"Cancer Statistics in Japan","year":"2009","author":"Foundation for Promotion of Cancer Research","key":"e_1_2_8_4_2"},{"key":"e_1_2_8_5_2","first-page":"75","article-title":"Natural history of and therapy for the indolent non\u2010Hodgkin\u2019s lymphomas","volume":"20","author":"Horning SJ","year":"1993","journal-title":"Semin Oncol"},{"key":"e_1_2_8_6_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1200\/JCO.1985.3.3.299","article-title":"Karnofsky memorial lecture. The low\u2010grade non\u2010Hodgkin\u2019s lymphomas: challenges and opportunities","volume":"3","author":"Rosenberg SA","year":"1985","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.020"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"e_1_2_8_11_2","first-page":"2253","article-title":"Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1\u2010positive MCL and cyclin D1\u2010negative MCL\u2010like B\u2010cell lymphoma","volume":"95","author":"Yatabe Y","year":"2000","journal-title":"Blood"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.11.2819"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2007.02207.x"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000174039.69656.2b"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1061"},{"key":"e_1_2_8_17_2","first-page":"904","article-title":"Laboratory evaluation of a new nitrogen mustard, 2\u2010[di\u2010(2\u2010chloroethyl)amino\u2010methyl]benzimidazole, and of other 2\u2010chloroethyl compounds","volume":"17","author":"Hirschberg E","year":"1957","journal-title":"Cancer Res"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402651"},{"key":"e_1_2_8_19_2","first-page":"485","article-title":"In vitro induction of apoptosis of neoplastic cells in low\u2010grade non\u2010Hodgkin\u2019s lymphomas using combinations of established cytotoxic drugs with bendamustine","volume":"86","author":"Chow KU","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199606000-00007"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24714"},{"volume-title":"World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues","year":"2001","author":"Jaffe ES","key":"e_1_2_8_23_2"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_27_2","unstructured":"CTCAE.Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0. Bethesda MD:National Cancer Institute US National Institutes of Health;2006. Available from URL:http:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcaev3.pdf."},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2010.01635.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2010.01635.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T23:11:55Z","timestamp":1697411515000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2010.01635.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,20]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1111\/j.1349-7006.2010.01635.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01635.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"type":"print","value":"1347-9032"},{"type":"electronic","value":"1349-7006"}],"subject":[],"published":{"date-parts":[[2010,8,20]]}}}